Cure My Disease

Don't miss your cure!

Home News Browse Soon ready About
Log in / Sign up
← Back to home

Jiangsu Biojetay Biotechnology Co., Ltd.

Clinical trials sponsored by Jiangsu Biojetay Biotechnology Co., Ltd., explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

  • New hope for hemophilia patients with inhibitors: STSP-0601 enters phase 3 trial Results expected Sep 2026 (estimated)
  • New injection aims to boost platelets in ITP patients Results expected Sep 2026 (estimated)
Browse trials soon ready across all sponsors →
Trials to join now! 1 Not yet finished but already full! 1
Sort by
  • New hope for hemophilia patients with inhibitors: STSP-0601 enters phase 3 trial

    Disease control Ongoing

    This Phase 3 trial is testing STSP-0601, an injectable drug, to control bleeding episodes in people with hemophilia A or B who have developed inhibitors (antibodies that block standard treatment). The study will enroll 40 participants aged 12 to 70 and measure how well the drug s…

    Phase 3 • Sponsor: Jiangsu BioJeTay Biotechnology Co., Ltd. • Aim: Disease control

    Last updated Aug 14, 2026 00:00 UTC

Cure My Disease

Helping patients find clinical trials that match their disease.

Why was Cure my disease built?

Explore

Home News Browse Glossary About Terms of use Contact us

This is a site from Cyber and Space